MILESTONE

Listing on the Taiwan Emerging Stock Market. (Code:TWO.7871)

Elixiron wins 2025 National Innovation Awards

EI-001 has received IND clearance from both the US FDA and Taiwan TFDA to initiate a Phase 2 clinical trial in patients with Vitiligo.

Elixiron Immunotherapeutics Inc. and National Yang Ming Chiao Tung University (NYCU) have signed a Memorandum of Understanding (MOU) to foster strategic research collaboration.

Vice President Hsiao Meets with the 2024 Outstanding Biotechnology Industry Award Recipients

Company relocates to Taipei Biotechnology Park

EI-1071 enters Phase II clinical trial for Alzheimer’s disease

Elixiron wins Startup Award at the Taiwan BIO Awards

EI-012 has been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC).

EI-1071 has received clearance from Taiwan's TFDA to initiate a Phase 2 clinical trial for Alzheimer's Disease.

Elixiron and NYCU Join Forces to Develop a New Immunotherapy for Head and Neck Cancer — a Novel Therapeutic Antibody Targeting Tumor-Associated Macrophages Fused with Interleukin-10 (IL-10).

Honored with the 'Emerging Star Award' at the 2nd Life Science Entrepreneurship Competition by MIT Technology Review

Elixiron Immunotherapeutics has entered into an out-licensing agreement with Pilatus Biosciences for the development and commercialization of EI-011 and EI-012.

EI-001 has been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of Hemophagocytic Lymphohistiocytosis (HLH).

EI-1071 has been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Received second round of funding from Part the Cloud Grant Program — funded by Bill Gates & Alzheimer’s Association

EI-1071 has completed enrollment and dosing for its Phase 1 SAD (US) and MAD (Taiwan) trials in healthy volunteers, with the clinical database now officially locked.

EI-001 has initiated a Phase 1 clinical trial in healthy volunteers in Australia.

EI-1071 has completed the Single Ascending Dose (SAD) enrollment and analysis in the US, while simultaneously initiating Phase 1 Multiple Ascending Dose (MAD) trials in Taiwan.

Elixiron Receives a $1 Million Grant from Bill Gates and the Alzheimer’s Association

Elixiron Immunotherapeutics has out-licensed specific indications and regional rights for EI-1071 to 4B Technologies.

EI-1071 received US FDA clearance to initiate a Phase 1 clinical trial in healthy volunteers.

1.Established the wholly-owned subsidiary Elixiron Immunotherapeutics (Shanghai) Co., Ltd. in Shanghai.
2.Acquired an exclusive license for the CSF-1R small molecule inhibitor EI-1071 from the Development Center for Biotechnology (DCB).

Established the wholly-owned subsidiary Elixiron Immunotherapeutics (Hong Kong) Limited in Hong Kong.

Obtained an exclusive license for the anti-IFN-$\gamma$ monoclonal antibody EI-001 from Chang Gung University.

Elixiron Immunotherapeutics Inc., a wholly-owned subsidiary, was established in Taipei.

Establishment of Elixiron Immunotherapeutics (Cayman) Limited